Top Page
Orexo AB
(OTC:ORX)
Orexo AB (ORX) vs. iShares MSCI Sweden ETF (EWD)
Orexo AB Business Overview & Revenue Model
Orexo AB Earnings Call Summary
Orexo AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 561.20M | 590.00M | 638.80M | 624.30M | 565.00M | 663.60M |
| Gross Profit | 489.70M | 517.90M | 549.90M | 521.70M | 486.10M | 598.00M |
| EBITDA | 28.00M | 58.60M | -32.30M | -73.90M | -141.30M | 16.80M |
| Net Income | -213.80M | -203.00M | -128.30M | -177.60M | -223.50M | -84.40M |
Balance Sheet | ||||||
| Total Assets | 533.40M | 594.80M | 786.60M | 1.11B | 1.27B | 1.23B |
| Cash, Cash Equivalents and Short-Term Investments | 121.30M | 123.30M | 171.00M | 351.80M | 504.10M | 505.30M |
| Total Debt | 495.60M | 476.00M | 473.80M | 539.60M | 550.50M | 291.00M |
| Total Liabilities | 730.40M | 721.10M | 727.70M | 915.10M | 924.10M | 674.40M |
| Stockholders Equity | -197.00M | -126.30M | 58.90M | 193.90M | 349.60M | 558.50M |
Cash Flow | ||||||
| Free Cash Flow | 24.20M | -37.20M | -113.90M | -180.50M | -281.80M | -172.90M |
| Operating Cash Flow | 25.00M | -32.60M | -95.00M | -156.60M | -229.00M | 16.80M |
| Investing Cash Flow | -20.70M | -5.30M | 200.80M | -234.70M | -52.90M | -189.10M |
| Financing Cash Flow | -13.30M | -15.50M | -70.10M | -21.40M | 250.60M | -111.30M |
Orexo AB Technical Analysis
Orexo AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | kr953.40M | ― | ― | ― | -8.79% | -91.09% | |
| ― | kr252.81M | ― | -161.07% | ― | ― | 22.73% | |
| ― | kr119.79M | ― | -3899.10% | ― | 1523.75% | 20.82% | |
| ― | €305.97M | ― | -34.87% | ― | -38.56% | 69.37% | |
| ― | kr468.48M | ― | ― | ― | 19.17% | 24.53% |
Orexo AB Corporate Events
Orexo AB is a commercial-stage pharmaceutical company specializing in developing drugs using advanced drug delivery technologies, with a focus on addressing opioid dependence in the US. In its Q3 2025 earnings report, Orexo AB reported total net revenues of SEK 118.7 million, a decrease from the previous year, and a negative EBITDA of SEK -9.8 million, impacted by costs associated with long-term incentive programs. Despite these financial challenges, the company highlighted promising developments in its AmorphOX® technology, including positive in-vivo data for a powder-based intranasal GLP-1 agonist medication and a significant partnership with BARDA for the development of OX390, a rescue medication for adulterated opioid overdoses. The US Commercial segment, which includes the Zubsolv® product for opioid use disorder, faced revenue declines due to foreign exchange rate impacts and reduced inventory levels at wholesalers. Looking forward, Orexo remains optimistic about its financial outlook for 2025, maintaining its full-year guidance and expecting improvements in Zubsolv sales in the fourth quarter. The company continues to focus on leveraging its AmorphOX® platform for future growth and expanding its pipeline of innovative drug delivery solutions.
Orexo AB reported a decrease in net revenues and a negative EBITDA for Q3 2025, with significant costs associated with LTIP programs impacting financial results. However, the company showcased positive in-vivo data for a new intranasal GLP-1 agonist medication supported by its AmorphOX® technology and secured a substantial award from BARDA for developing an intranasal rescue medication, indicating potential future growth and innovation.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK23.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
Orexo AB has announced the appointment of its Nomination Committee for the Annual General Meeting scheduled for May 7, 2026. The committee, representing approximately 34% of the company’s voting power, includes members from Novo Holdings, The Danish Labour Market Supplementary Pension, and private investors. This strategic move ensures diverse representation and stakeholder engagement in Orexo’s governance, potentially impacting its future strategic decisions.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK23.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
Orexo AB has announced that it will release its Q3 2025 Interim Report on October 23, followed by a presentation featuring updates on its partnership with BARDA and the OX390 project. This event will include insights from the CEO, CFO, and Chief Medical Officer, and will be accessible via live audiocast and teleconference, highlighting the company’s ongoing strategic developments and stakeholder engagement.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK23.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
Orexo AB is relocating to new premises in Uppsala Science Park as part of a strategic initiative to enhance its research and development capabilities. This move aims to foster greater collaboration, innovation, and sustainability while offering state-of-the-art laboratories and flexible office spaces. The new location is expected to reduce costs through efficient space utilization and lower energy consumption, thereby strengthening Orexo’s ability to attract and retain talent, which is crucial for developing future innovative medicines.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK23.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
Orexo AB’s US subsidiary has received an $8 million award from BARDA to support the development of OX390, an intranasal rescue medication for opioid overdoses. This funding is part of a larger potential $50.9 million package contingent on meeting specific milestones. OX390 aims to address the growing issue of adulterated opioid overdoses in the US using Orexo’s AmorphOX technology, with the company retaining commercial rights upon FDA approval.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK23.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
Orexo AB announced its participation in the 16th Annual Healthcare Conference organized by Pareto Securities, scheduled for September 16, 2025, in Stockholm, Sweden. During the event, Robert Rönn, SVP and Head of R&D, will present the company’s developments, and both he and Lena Wange, Investor Relations Director, will be available for one-on-one meetings. This participation highlights Orexo’s ongoing engagement with the healthcare investment community and its commitment to showcasing its advancements in pharmaceutical solutions, potentially enhancing its industry positioning and stakeholder relations.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK23.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
Orexo AB announced positive results from a preclinical study using its AmorphOX technology to develop a powder-based intranasal formulation of semaglutide, a GLP-1 receptor agonist. The study showed that the intranasal formulations achieved significantly higher plasma concentrations and bioavailability compared to oral tablets, suggesting potential for needle-free delivery and improved patient adherence. This advancement could enhance Orexo’s strategic positioning by enabling partnerships to expand the use of this novel delivery method for more efficient treatment options.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK21.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.